Nika Pharmaceuticals, Inc. (OTCPK: NIKA)
Health Care · Pharmaceuticals · US
$0.42
-17.65% today · -4.8% 1Y
Nika Pharmaceuticals, Inc. (OTCPK: NIKA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $441.70M and employs 0 people.
Over the last twelve months the share price has lost 4.8%, trading between 0.20 and 0.98.
Tweenvest scores Nika Pharmaceuticals, Inc. across four factors: quality 5/100. Its strongest factor is quality.
NIKA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $441.70M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- -2.10
- 52-week high
- $0.98
- 52-week low
- $0.20
- Avg volume (3M)
- —
- Shares outstanding
- 1.05B
- Employees
- 0
- Next earnings
- —
About Nika Pharmaceuticals, Inc.
Nika Pharmaceuticals Inc., a pharmaceutical enterprise headquartered in Henderson, Nevada, focuses on the creation of medications to address a broad spectrum of health conditions. Its research and development efforts target serious diseases including HIV/AIDS, hepatitis B and C, rheumatoid arthritis, cancer, and diabetes. The company's product line features antiviral treatments and nutritional supplements, notably providing a specialized thymus nuclear glycoprotein for the management of HIV. Originally established in 2000, the organization was previously known as Centennial Growth Equities Inc. before adopting its current name, Nika Pharmaceuticals, Inc., in May 2022.
- ISIN
- US1513411041
- Founded
- 2000
- Listed since
- Mar 14, 2024
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.